Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer

Affiliations

¹ Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA;; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
² Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA;; Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

Comment

Daniel J Crona et al. Ann Transl Med. 2016 Oct.

. 2016 Oct;4(Suppl 1):S64.

doi: 10.21037/atm.2016.10.39.

¹ Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA;; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
² Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA;; Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

No abstract available

Conflict of interest statement

Y.E.W. received research funding from Astellas and Janssen and Tokai. D.J.C. stated no conflicts of interest.

Plasma AR and abiraterone-resistant prostate cancer.
Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, Carreira S, Goodall J, Wingate A, Ferraldeschi R, Tunariu N, Flohr P, De Giorgi U, de Bono JS, Demichelis F, Attard G. Romanel A, et al. Sci Transl Med. 2015 Nov 4;7(312):312re10. doi: 10.1126/scitranslmed.aac9511. Sci Transl Med. 2015. PMID: 26537258 Free PMC article.

1. Attard G, Reid AH, Olmos D, et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69:4937-40. 10.1158/0008-5472.CAN-08-4531 - DOI - PubMed
1. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90. 10.1126/science.1168175 - DOI - PMC - PubMed
1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97. 10.1056/NEJMoa1207506 - DOI - PubMed
1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. 10.1056/NEJMoa1014618 - DOI - PMC - PubMed
1. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92. 10.1016/S1470-2045(12)70379-0 - DOI - PubMed